0000899243-20-033215.txt : 20201209 0000899243-20-033215.hdr.sgml : 20201209 20201209195426 ACCESSION NUMBER: 0000899243-20-033215 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201207 FILED AS OF DATE: 20201209 DATE AS OF CHANGE: 20201209 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Bolzon Bradley J PhD CENTRAL INDEX KEY: 0001354345 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37923 FILM NUMBER: 201379106 MAIL ADDRESS: STREET 1: ONE SANSOME STREET STREET 2: SUITE 3630 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CRISPR Therapeutics AG CENTRAL INDEX KEY: 0001674416 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 473173478 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 BUSINESS PHONE: 6173154600 MAIL ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-12-07 0 0001674416 CRISPR Therapeutics AG CRSP 0001354345 Bolzon Bradley J PhD C/O CRISPR THERAPEUTICS, INC. 610 MAIN STREET CAMBRIDGE MA 02139 1 0 0 0 Common Shares 2020-12-07 4 S 0 4809 144.3926 D 513381 I See Footnote Common Shares 2020-12-07 4 S 0 2762 145.4293 D 510619 I See Footnote Common Shares 2020-12-07 4 S 0 4203 146.566 D 506416 I See Footnote Common Shares 2020-12-07 4 S 0 24077 147.4008 D 482339 I See Footnote Common Shares 2020-12-07 4 S 0 12703 148.4475 D 469636 I See Footnote Common Shares 2020-12-07 4 S 0 9416 149.409 D 460220 I See Footnote Common Shares 2020-12-07 4 S 0 7067 150.5712 D 453153 I See Footnote Common Shares 2020-12-07 4 S 0 600 151.3167 D 452553 I See Footnote Common Shares 2020-12-07 4 S 0 10098 153.4396 D 442455 I See Footnote Common Shares 2020-12-07 4 S 0 4300 154.4054 D 438155 I See Footnote Common Shares 2020-12-07 4 S 0 12123 155.3594 D 426032 I See Footnote Common Shares 2020-12-07 4 S 0 4457 156.5301 D 421575 I See Footnote Common Shares 2020-12-07 4 S 0 8582 157.5383 D 412993 I See Footnote Common Shares 2020-12-07 4 S 0 15260 158.4057 D 397733 I See Footnote Common Shares 2020-12-07 4 S 0 8453 159.4791 D 389280 I See Footnote Common Shares 2020-12-07 4 S 0 9397 160.4975 D 379883 I See Footnote Common Shares 2020-12-07 4 S 0 17627 161.5719 D 362256 I See Footnote Common Shares 2020-12-07 4 S 0 14270 162.4034 D 347986 I See Footnote Common Shares 2020-12-07 4 S 0 800 163.1313 D 347186 I See Footnote Common Shares 40648 D Common Shares 1336088 I See Footnote Common Shares 7922 I See Footnote Common Shares 1192139 I See Footnote Common Shares 34977 I See Footnote Common Shares 38772 I See Footnote Common Shares 90730 I See Footnote The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $144.00 to $144.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. These securities are held of record by Versant Venture Management, LLC ("VVM LLC"). The Reporting Person is a managing member of VVM LLC and the Reporting Person may be deemed to indirectly beneficially own the securities through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $145.00 to $145.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $146.00 to $146.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $147.00 to $147.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $148.00 to $148.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (6) to this Form 4. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $149.00 to $149.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (7) to this Form 4. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $150.00 to $150.91, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (8) to this Form 4. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $151.15 to $151.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (9) to this Form 4. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $152.90 to $153.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (10) to this Form 4. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $154.05 to $154.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (11) to this Form 4. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $155.00 to $155.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (12) to this Form 4. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $156.00 to $156.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (13) to this Form 4. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $157.01 to $157.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (14) to this Form 4. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $158.00 to $158.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (15) to this Form 4. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $159.00 to $159.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (16) to this Form 4. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $160.01 to $160.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (17) to this Form 4. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $161.00 to $161.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (18) to this Form 4. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $162.00 to $162.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (19) to this Form 4. The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $163.00 to $163.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the ranges set forth in this footnote (20) to this Form 4. These securities are held of record by Versant Venture Capital IV, L.P. ("VVC IV"). Versant Ventures IV, LLC ("VV IV") is the sole general partner of VVC IV and may be deemed to have voting and investment power over the securities held by VVC IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. These securities are held of record by Versant Side Fund IV, L.P. ("VSF IV"). VV IV is the sole general partner of VSF IV and may be deemed to have voting and investment power over the securities held by VSF IV and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV IV and may be deemed to indirectly beneficially own the securities through his interest in VV IV. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. These securities are held of record by Versant Venture Capital V, L.P. ("VVC V"). Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. These securities are held of record by Versant Affiliates Fund V, L.P. ("VAF V"). VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. These securities are held of record by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"). VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. These securities are held of record by Versant Venture Capital V (Canada) LP ("VVC CAN"). Versant Ventures V GP-GP (Canada), Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the securities through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any. s/ Robin L. Praeger, attorney-in-fact for Bradley Bolzon 2020-12-09